Document:

EX-10.11

 Exhibit 10.11 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT MAGENTA
THERAPEUTICS, INC. TREATS AS PRIVATE OR CONFIDENTIAL. 
 Master Services Agreement 

BETWEEN 
 Heidelberg Pharma Research GmbH,

 with its registered offices at Schriesheimer Str. 101, 68526 Ladenburg, Germany 

(hereafter “HDPR”) 

AND 
 Magenta Therapeutics, Inc. 

with its registered offices at 100 Technology Square, 5th Floor, Cambridge, MA 02139, USA 

(hereafter “Customer”) 

(each also referred to as a “Party” or collectively as the “Parties”) 

  
 1 

 Table of Contents 

 

							
	 Recitals
	 		  	 	3	 
			
	 1
	 	 Definitions
	  	 	3	 
			
	 2
	 	 Principles of performance of the Agreement; General obligations
	  	 	5	 
			
	 3
	 	 HDPR’s specific obligations
	  	 	6	 
			
	 4
	 	 Subcontracting
	  	 	7	 
			
	 5
	 	 Service Fee; payment
	  	 	8	 
			
	 6
	 	 Quality
	  	 	9	 
			
	 7
	 	 Customer’s inspection rights
	  	 	9	 
			
	 8
	 	 Transfer of ownership and risk; Delivery; Acceptance
	  	 	9	 
			
	 9
	 	 Warranties of HDPR
	  	 	10	 
			
	 10
	 	 Customer’s use of Goods and representations
	  	 	11	 
			
	 11
	 	 No Other Warranty
	  	 	11	 
			
	 12
	 	 Liability
	  	 	11	 
			
	 13
	 	 Indemnification
	  	 	12	 
			
	 14
	 	 Insurance
	  	 	13	 
			
	 15
	 	 Intellectual Property
	  	 	13	 
			
	 16
	 	 Confidentiality
	  	 	13	 
			
	 17
	 	 Force majeure
	  	 	14	 
			
	 18
	 	 General provisions
	  	 	15	 
			
	 19
	 	 Notices
	  	 	16	 
			
	 20
	 	 Term and termination
	  	 	16	 
			
	 21
	 	 Applicable law and jurisdiction
	  	 	17	 

  
 2 

 Recitals 

This Agreement is made this 22nd day of May, 2019. 

WHEREAS: 
  

	A.	 Customer and HDPR have concluded an Exclusive Research, Development Option and License Agreement dated March 1st 2018 (the “ERDOLA”), setting forth the terms and conditions for a target-exclusive license for Customer to HDPR’s technology of amatoxin-based antibody drug conjugates, as well
as the framework for the negotiation of a separate agreement between Customer and HDPR on the supply of Amanitin Toxin Constructs (the term is used in this Agreement as defined in the ERDOLA); 

 

	B.	 HDPR is the owner of certain technology and patent rights regarding the Amanitin Toxin Constructs and is
subcontracting process development, manufacturing and supply services of active pharmaceutical ingredients and intermediates related to the Amanitin Toxin Constructs to [**]; and 

 

	C.	 Customer will during the term of this Agreement from time to time request HDPR to perform certain services
related to the manufacturing of Amanitin Toxin Constructs, and HDPR is willing to provide such services through its existing relationship with [**]; and 

  

	D.	 This Agreement shall exclusively govern the relationship of the Parties with regard to the provision of the
Services (as defined below) by HDPR to the Customer, and no general terms and conditions of a Party shall be binding to the other Party. 

NOW THEREFORE, in consideration of the premises and the mutual covenants and agreements contained herein and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
 1 Definitions 

For the purpose of this Agreement: 
  

	a)	 “Affiliate” means any Person directly or indirectly, controlling,
controlled by, or under common control with another Person. For purposes of this definition, “controlling” (including, “controlled by” and “under common control”) shall mean: (a) ownership of more than fifty
percent (50%) of the equity capital or other ownership interest in or of an entity; (b) the power to control or otherwise direct the affairs of an entity; (c) in the case of non-stock organizations,
the power to control the distribution of profits of an entity; or (d) such other relationship as, in fact, results in actual control over the management, business, and affairs of an entity; 

 

	b)	 “Agreement” means this Master Services Agreement, together with all its appendices and
documents incorporated by reference therein and part hereof, as amended or modified from time to time in accordance with the terms hereof; 

  

	c)	 “Applicable Law” means any law, statute, rule, regulation, order, judgement or
ordinance of any governmental or Regulatory Authority or agency that may be in effect from time to time during the Term and applicable to a particular activity or country hereunder; 

  
 3 

	d)	 “Business Day” means any day that is not a Saturday, a Sunday on which banking institutions in
Frankfurt A.M., Germany, Zurich, Switzerland and New York, New York are open for business. 

  

	e)	 [**] 

  

	f)	 “Confidential Information” means any and all
non-public and proprietary information, whether technical or non-technical, oral or written, that is disclosed by one Party or its Affiliates to the other Party or its
Affiliates in connection with this Agreement. Notwithstanding the foregoing, “Confidential Information” shall not include any information or any portion thereof which: 

 

	 	(i)	 was known to the recipient or any of its Affiliates, as evidenced by its written records, before receipt
thereof under this Agreement; 

  

	 	(ii)	 is disclosed to the recipient or any of its Affiliates, without restriction, after the Effective Date by a
Third Party who has the right to make such disclosure; 

  

	 	(iii)	 is or becomes part of the public domain through no breach of this Agreement by the recipient or any of its
Affiliates; or 

  

	 	(iv)	 is independently developed by or for the recipient or any of its Affiliates, as evidenced by its written
records, by individuals or entities who have not had access to the disclosing Party’s Confidential Information that was disclosed under this Agreement. 

The Confidential Information may include data, know-how, formulae, processes, designs, sketches,
photographs, plans, drawings, specifications, samples, reports, studies, data, findings, inventions, ideas, production facilities, machines, production capacities, prices, market share, research and development projects, and other market data. The
terms of this Agreement will constitute Confidential Information of both Parties. For clarity, specific aspects or details of Confidential Information will not be deemed to be within the public domain or in the possession of the recipient merely
because the Confidential Information is embraced by more general information in the public domain or in the possession of the recipient. Further, any combination of Confidential Information will not be considered in the public domain or in the
possession of the recipient merely because individual elements of such Confidential Information are in the public domain or in the possession of the recipient, unless the combination and its principles are in the public domain or in the possession
of the recipient. 
  

	g)	 “Effective Date” means the date first written above; 

 

	h)	 “Facility” means [**] premises where the Goods are made ready for shipment.

  

	i)	 “Good Manufacturing Practices” or “GMP” means all Applicable Laws relating to
manufacturing practices for products (including ingredients, testing, storage, handling, intermediates, bulk and finished products) promulgated by the FDA and any other Regulatory Authority (including, without limitation, the EMA or member state
level and Swissmedic) having jurisdiction over the manufacturing practices for products, including standards in the form of Applicable Laws, guidelines, advisory opinions and compliance policy guides and current interpretations of the applicable
authority or agency thereof (as applicable to pharmaceutical and biological products and ingredients), as the same may be updated, supplemented or amended from time to time. 

  
 4 

	j)	 “Goods” means the product(s), chemical(s), intermediate(s), substance(s) or compound(s)
created through the performance of the Services by HDPR; 

  

	k)	 “Intellectual Property Right” means any and all intellectual property rights throughout the
world, however denominated, including if registered or not (including patents, copyrights, trade secrets, trade marks, general know-how, processes, etc.); 

 

	l)	 “Non-Compliance” or
“Non-Compliant Good” has the meaning as defined in Section 8.3; 

  

	m)	 “Party” means either HDPR or Customer, as the case may be, and “Parties” shall mean
HDPR and the Customer; 

  

	n)	 “Project Leader” means the responsible person of either Customer or HDPR for planning,
managing, directing and overseeing specific activities regarding the Agreement; 

  

	o)	 “Project Management Fee” means the consideration payable to HDPR by Customer for the provision
of project management for Services as set forth in the applicable Work Order; 

  

	p)	 “Proposal” means a description of the Services to be provided by HDPR to Customer, including,
without limitation, a description of any Goods to be created through the performance of the Services, and the Service Fees, timelines or cycle times for such Services and Goods; 

 

	q)	 “Quality Agreement” means the agreement concluded by the Parties, which shall govern the
responsibilities related to quality systems, quality requirements, quality control, testing, Reports, audits, complaints, inspections and release for the Goods; as incorporated herein by reference and part hereof; 

 

	r)	 “Report” means the description of the performed Services by HDPR in written form and in the
agreed depth of detail as further specified in the Agreement; 

  

	s)	 “Section” means a section of this Agreement; 

 

	t)	 “Services” means those development, synthesis, analytical purification, (pre-) formulation, packaging, storage, stability, release testing, quality control services or other related services to be provided by HDPR to Customer (including the targeted quantity of Goods to be delivered),
as further defined in the applicable Work Order; 

  

	u)	 “Service Fee” means the consideration payable to HDPR by Customer for the provision of every
particular Service set forth in the applicable Work Order and as set out in Section 5; 

  

	v)	 “Third Party” means any Person other than (i) a Party, (ii) an
Affiliate of a Party or (iii) [**]. 

  

	w)	 “Work Order” means a description of the individual Services to be performed by HDPR,
including, without limitation, a description of any Goods to be created through the performance of the Services, and the Service Fees, timelines or cycle times for such Services and Goods; as incorporated herein by reference and part hereof.

 2 Principles of performance of the Agreement; General obligations 

2.1 Upon receipt of Customer’s request to perform certain services, HDPR will, as a rule not more than [**] of such request (the
“Proposal Preparation Timeframe”), prepare a Proposal for such services. HDPR will employ commercially reasonable efforts to comply with the Proposal Preparation Timeframe. If the Proposal Preparation Timeframe cannot be met HDPR will
promptly inform Customer about the reasons and the envisaged new timeline. If Customer agrees to the terms of such Proposal, it shall send to HDPR the signed Proposal as agreed by the Parties within the timeline set forth in the Proposal, for
countersignature by HDPR, which countersignature shall take place without delay upon receipt of the signed Proposal by HDPR and shall not be unreasonably withheld. Upon signature by both Parties the Proposal shall become a Work Order that will be
binding for both Parties. For the avoidance of any doubt, HDPR shall not be obliged to perform any Services if Customer has not, in its sole discretion, sent a signed Proposal to HDPR. 

  
 5 

 2.2 Both Parties shall always cooperate, communicate and act diligently and in good faith in
order to ensure the proper performance of the Agreement. HDPR undertakes to make every commercially reasonable effort to implement requested amendments to each Work Order. Such amendments of any Work Order, including any adjustment of the Service
Fee and estimated term, if applicable, shall be in writing and become binding upon the Parties execution of the amended Work Order. HDPR shall promptly notify Customer of any unanticipated adverse effect or any adverse event that becomes known to it
occurring during the performance of the Agreement. 
 2.3 Customer has the obligation to render all necessary support reasonably requested
by HDPR to enable a proper performance of the Agreement, such as, but not limited to, taking and notifying decisions, accepting or declining requests, giving or refusing consents, etc. 

2.4 The day-to-day management of the Agreement shall be the
responsibility of Customer’s Project Leader and HDPR’s Project Leader. The Customer’s Project Leader shall be the ultimate authority with respect to all Agreement related issues and decisions on behalf of the Customer and hence shall
be assumed to have all necessary authority and power to take any and all actions on behalf of Customer with respect to such day-to-day issues and decisions. In addition,
the Parties shall appoint a joint program team composed of qualified representatives from HDPR and Customer, with the option to include representatives from [**] from time to time whenever both Parties agree that this would be necessary or useful
(the “Program Team”). The Program Team shall be responsible for carrying out the Work Order(s). The Program Team shall meet at least every other week by teleconference and shall meet quarterly in person, unless the Parties mutually agree
otherwise. HDPR shall be responsible for coordinating meetings and meeting minutes and circulating meeting minutes to the Program Team as soon as reasonably practicable for comments and approval. For the avoidance of doubt, the Program Team shall
not have the authority to amend or modify this Agreement, the Quality Agreement, or any Work Order. Any additional responsibilities of the Program Team will be specified in the applicable Work Order. 

2.5 In case of any discrepancies between the provisions of the body of this Agreement with any of its appendices or documents incorporated by
reference herein, the body of this Agreement shall take precedence over all and any such appendices or documents; provided, however, that such appendices or documents shall expressly modify, amend or supersede a specific Section of the body
of this Agreement if such appendices or documents expressly reference to the Section being modified, amended or superseded. Notwithstanding the foregoing, if an amendment or a modification of this Agreement is expressly agreed in a specific Work
Order only, such amendment or modification shall only apply for such specific Work Order. The Quality Agreement (if any) shall take precedence in all matters regarding the standard of quality of the Services. 

3 HDPR’s specific obligations 
 3.1
As the Parties consider the Services as of an experiential and development nature, subject to Sections 3.2 to 3.5 below, HDPR cannot and does not guarantee the achievement of any specific or particular result or outcome nor guarantee
completing thereof to or within a defined deadline. For avoidance of doubt, the foregoing sentence shall not relieve HDPR of its obligation to provide the Services or Goods in accordance with this Agreement, the Quality Agreement, or the applicable
Work Order. 

  
 6 

 3.2 HDPR shall cause [**] to perform the Services (a) in accordance with this
Agreement, the Quality Agreement and each Work Order, including within the agreed time targets, (b) in a manner that meets professional and industry standards reasonably to be expected from a first-class provider of similar services in similar
circumstances and (c) in compliance with all Applicable Laws at the place of performance thereof. 
 3.3 HDPR shall ensure that [**]
reserves time slots and qualified personnel as necessary to perform the Services, as agreed in each Work Order. 
 3.4 HDPR shall ensure
that the personnel that [**] on behalf of HDPR causes to be applied in the performance of the Agreement shall be appropriately qualified and experienced for the tasks that they are to perform. 

3.5 HDPR shall ensure that any machinery and equipment that [**] on behalf of HDPR provides or causes to be applied in the performance of the
Agreement shall be of an appropriate quality and, as required by normal practice, shall be certified and approved by the relevant body or organisation. 

3.6 HDPR shall cause [**] to have and maintain, at its own cost, any and all licenses, permits and other authorisations, which are required
for its performance of this Agreement and the Services provided hereunder. 
 3.7 HDPR shall not be liable for any raw material supply
issues beyond its or [**] direct control. The impact of any quality or delivery issues shall be discussed in good faith between Customer and HDPR and the Work Order revised accordingly. HDPR will employ commercially reasonable efforts, and shall
cause [**] to employ commercially reasonable efforts to find an adequate replacement, taking into account the timelines envisaged in the Work Order. 

3.8 HDPR shall cause [**] to perform the Services at its facilities as set forth in Annex 3.8. If [**] intends to perform any part of
the Services at any other facility, HDPR shall seek Customer’s prior written approval before doing so, such approval not to be unreasonably withheld, delayed or conditioned, and Annex 3.8 shall be amended accordingly if Customer provides
its approval as aforesaid. 
 3.9 Notwithstanding the delegation of activities to [**] hereunder, HDPR shall remain primarily responsible
for its obligations (and the obligations of [**]) under this Agreement. 
 4 Subcontracting 

HDPR may allow [**] to subcontract the Services to subcontractors agreed between [**] and HDPR. If [**] intends to subcontract any part of the
Services, HDPR shall (a) notify Customer in writing, including the identity of the proposed subcontractor and the Services to be subcontracted and (b) cause [**] to appropriately qualify the potential subcontractor according to [**] vendor
qualification procedure and conclude a quality agreement with such subcontractor enforcing the terms of this Agreement and the Quality Agreement, with respect to (a)-(b), before subcontracting such activity. In addition, any documentation on
supplier qualification and the quality agreement shall be available for Customer review in the course of Customer’s audits pursuant to Section 7.1. Customer understands and acknowledges that parts of the documentation may be redacted to
comply with [**] confidentiality obligations. However, if Customer should require the disclosure of redacted information in order to comply with its obligations towards applicable authorities it may request disclosure of such information, and HDPR
shall cause [**] to discuss in good faith disclosure of such information with the corresponding subcontractor. In any event, HDPR shall be responsible for oversight of the subcontracted Services and all obligations under this Agreement and the
Quality Agreement shall remain vested in HDPR. 

  
 7 

 5 Service Fee; payment 

5.1 In consideration of HDPR providing the Services to Customer, Customer shall pay HDPR Service Fees specified in the applicable Work Order.
The Service Fee will be agreed in each Work Order for Services. 
 5.2 Customer shall pay HDPR according to the payment schedule in the
applicable Work Order. 
 5.3 All Goods are shipped FCA (Incoterms 2010) [**] loading docks at the Facility. 

5.4 The amount, weight and quantity of Goods will be measured or weighed at the Facility. 

5.5 The Service Fee does not include any state or local taxes, duties, governmental or similar charges, VAT, customs duties or any additional
costs (such as but not limited to insurance costs, etc.). Any such costs, if any, will be additionally charged to Customer. 
 5.6 Costs for
disposal of any Goods or unused raw materials are not included in the Service Fee. Such costs will therefore additionally be charged to Customer at cost, unless such Goods or unused raw material are required to be disposed on account of HDPR’s
gross negligence, fraud, intentional misconduct or breach of this Agreement, in which case, HDPR shall pay for the cost of such disposal. 

5.7 Third Party costs for analytical services, specific chromatography columns, reagents or reference standards will be described in the
applicable Work Order. 
 5.8 HDPR will cause [**] to store and insure the Goods to be delivered to Customer free of charge for a period of
[**] following the date of release. Any storage and insurance exceeding this period of time will additionally be invoiced to Customer at reasonable cost. In case of postponement of the delivery date and/or the project at Customer’s request,
storage and insurance of Goods and raw materials will additionally be charged to Customer at reasonable cost. 
 5.9 Prices for raw
materials will be described in the applicable Work Order. 
 5.10 Invoices for Service Fees and other amounts payable to HDPR are payable by
Customer within [**] of the date an invoice is received by Customer. If Customer disputes all or any portion of an invoice, then the Parties will attempt to resolve such dispute in good faith for [**] following Customer’s notice to HDPR that it
disputes an invoice or portion thereof. In furtherance of the foregoing dispute resolution process, HDPR will maintain written records of the fees and expenses charged to Customer with respect to the Services. HDPR shall retain such records for [**]
after the completion or termination of the Services to which they pertain and shall make such records available to Customer during normal business hours upon reasonable advanced notice. In the event the Parties are unable to resolve a payment
dispute in such [**] period, then either Party may initiate dispute resolution in accordance with Section 21. Customer will have no obligation to pay any amounts disputed in good faith until such dispute is finally resolved and no appeal can be
taken, except that HDPR may request payment of a portion of the invoice to fulfill its payment obligations towards [**], such amount to be repaid to Customer in case that no amounts are owed by Customer as a result of the dispute resolution. If
amounts are finally determined to be owed to HDPR, Customer will pay such amounts to HDPR within [**] of such determination (including interest due). In the event that any payment due under this Agreement is not made when due, the payment shall
accrue interest calculated on a daily basis from the due date until full payment at the rate of EURIBOR plus [**] per year. 

  
 8 

 6 Quality 

6.1 The appropriate level of quality for the specific Services (GMP, non GMP, etc.) will be defined in the Work Order. 

6.2 If not defined in the Work Order, the responsibilities related to quality systems, quality requirements, quality control, testing and
manufacturing records, audits, complaints, inspections and release of Goods shall be governed by the Quality Agreement. 
 7 Customer’s inspection
rights 
 7.1 Customer’s audit inspection and audit rights are set forth in the Quality Agreement. 

8 Transfer of ownership and risk; Delivery; Acceptance 

8.1 Delivery of Goods shall be deemed completed, and risk of loss or damage with respect thereto, shall pass to Customer upon delivery to the
carrier. Title to Goods shall pass to Customer upon complete payment of the corresponding invoice. 
 8.2 Subject to Sections 3.2 to
3.5 above, delivery times of HDPR shall not be regarded as binding, and delays of anticipated delivery shall not entitle Customer to claim damages resulting from any such delay. However, HDPR will employ commercially reasonable efforts, and
will cause [**] to employ commercially reasonable efforts to comply with the timelines agreed in the Work Orders. In case that a timeline cannot be met HDPR will notify Customer promptly upon receipt of knowledge on such deviation. 

8.3 Within [**] of any Goods, Customer shall examine any such Goods and Services. Notice of all claims arising out of non-compliance with the agreed level of quality (e.g. GMP), specifications, compliance with this Agreement, the Quality Agreement, Applicable Law or the applicable Work Order, or deliverables or any shortages or
defects of delivered Goods or Services (any of the before a “Non-Compliance” or “Non-Compliant Good”), shall be given in writing to
HDPR within [**] (the “Notice of Rejection”). With respect to any Non-Compliance, which would not be apparent from a reasonable visual inspection on delivery and, in case of any hidden or
latent Non-Compliance, Notice of Rejection shall be given not later than [**] from the time Customer discovers or should have discovered the relevant Non-Compliance,
however in no event later than (i) within [**], or (ii) the expiry of the shelf life of the affected Goods; whatever is shorter. The failure of Customer or its designees to notify HDPR of any
Non-Compliance of a Good in the manner set forth herein above shall constitute confirmation of the acceptance thereof. 

8.4 If HDPR disputes the Notice of Rejection within [**], then the Parties shall investigate Customer’s assertion of Non-Compliance and discuss in good faith a resolution of any such disagreement regarding the Goods or Services. The Parties shall act promptly and shall cooperate fully and in good faith in such investigations. If
the Parties do not reach an agreement, then HDPR and Customer shall (each acting reasonably and in good faith) mutually elect an independent Third Party laboratory or expert (acting as an expert and not an arbitrator) to determine if the Goods or
Services are Non-Compliant Goods and make a determination regarding the cause of the Non-Compliance. Such results shall be binding upon both Parties. The cost of the
testing and evaluation by the expert shall be borne entirely by the Party against whom such laboratory’s or expert’s findings are made. In the event of Non-Compliance, Customer shall have the
remedies set forth in Article 12. 

  
 9 

 9 Warranties of HDPR 

HDPR hereby represents, warrants and covenants to Customer as of the Effective Date as follows: 

 

	 	a)	 HDPR has been duly organized and is validly subsisting and in good standing under the laws of the jurisdiction
of its organization, and has all requisite power and authority, corporate or otherwise, to execute, deliver and perform this Agreement; 

  

	 	b)	 HDPR has the right to enter into this Agreement and this Agreement is a legal and valid obligation binding upon
HDPR and enforceable in accordance with its terms (including the right to enforce the actions or obligations taken by [**] on behalf of HDPR under this Agreement or any Work Order); 

 

	 	c)	 the execution, delivery and performance of this Agreement by HDPR has been duly authorized by all necessary
corporate action; 

  

	 	d)	 HDPR has not made and will not make any commitments to Third Parties inconsistent with or in derogation of
HDPR’s obligations under this Agreement and HDPR is not subject to any obligations that would prevent it from entering into or carrying out its obligations under this Agreement; 

 

	 	e)	 all delivered Goods shall, at the time of delivery, (i) conform to the specifications agreed between HDPR
and Customer in the Work Order and (ii) comply with this Agreement, the Quality Agreement and Applicable Law; 

  

	 	f)	 the Services shall be provided (a) in accordance with this Agreement, the Quality Agreement and each Work
Order, including within the agreed time targets, (b) in a manner that meets professional and industry standards reasonably to be expected from a first-class provider of similar services in similar circumstances and (c) in compliance with
all Applicable Laws at the place of performance thereof. 

  

	 	g)	 it has not and shall not, and shall cause [**] (or any other Third Party acting on HDPR’s behalf) to not,
at any time from and after the Effective Date, retain or use the services of (i) any Person of whom HDPR, respectively [**], has knowledge that such Person is debarred under 21 U.S.C. § 335a or (ii) any Person of whom HDPR,
respectively [**] (or such other Third Party), has knowledge that such Person has been convicted of a crime as defined under the FDCA, in each case, in any capacity associated with or related to the Services to be provided under this Agreement. HDPR
agrees to immediately disclose in writing to Customer if it receives knowledge that any of its or [**] employees or agents is debarred, or if any action or investigation is pending or, to the best of HDPR’s knowledge, is threatened in relation
to the debarment of HDPR or any person performing Services or providing services in any capacity in connection with this Agreement; 

  

	 	h)	 to HDPR’s knowledge as of the Effective Date, the performance of Services and the Goods provided under
this Agreement shall not infringe the intellectual property rights of any Third Party; 

  

	 	i)	 all records and reports required to be maintained by HDPR or [**] under Applicable Law, including GMP, where
applicable, shall be accurate and complete in all material respects; 

	 	j)	 it shall not terminate its agreement with [**] relating to the process development, manufacturing and supply
services of Amanitin Toxin Constructs without cause and shall notify Customer promptly if such agreement is terminated; and 

  

	 	k)	 each of HDPR’s and [**] employees, consultants, agents or any contractors performing Services under a Work
Order are bound by written obligations or Applicable Law to assign all of their rights, title and interests in, to and under any intellectual property resulting from their performance of Services to HDPR or [**], as applicable.

  
 10 

 10 Customer’s use of Goods and representations 

Customer hereby represents, warrants and covenants to HDPR as of the Effective Date as follows: 

 

	 	a)	 Customer has been duly organized and is validly subsisting and in good standing under the laws of the
jurisdiction of its organization, and has all requisite power and authority, corporate or otherwise, to execute, deliver and perform this Agreement; 

  

	 	b)	 Customer has the right to enter into this Agreement and this Agreement is a legal and valid obligation binding
upon Customer and enforceable in accordance with its terms; 

  

	 	c)	 the execution, delivery and performance of this Agreement by Customer has been duly authorized by all necessary
corporate action; 

  

	 	d)	 Customer has not made and will not make any commitments to Third Parties inconsistent with or in derogation of
Customer’s obligations under this Agreement and Customer is not subject to any obligations that would prevent it from entering into or carrying out its obligations under this Agreement; and 

 

	 	e)	 Customer will use any Goods manufactured under this Agreement in strict compliance with all Applicable Laws.

 11 No Other Warranty 
 THE
REPRESENTATIONS AND WARRANTIES EXPRESSLY SET FORTH IN THIS AGREEMENT ARE THE SOLE REPRESENTATIONS AND WARRANTIES MADE BY EITHER PARTY TO THE OTHER AND, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THE PARTIES HEREBY DISCLAIM ANY AND ALL OTHER
REPRESENTATIONS OR WARRANTIES OF ANY KIND WHATSOEVER, EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 

12 Liability 
 12.1 If Customer issues a
Notice of Rejection (other than for shortages, which are governed by Section 12.2), and (a) if HDPR does not contest (or does not contest within [**]) or (b) if the independent Third Party laboratory or expert confirms such Non-Compliance pursuant to Section 8.4, with respect to each, then HDPR’s sole and exclusive liability and Customer’s exclusive remedy with respect to
Non-Compliant Goods shall either be replacement of such Non-Compliant Goods without charge or the refund of the Service Fees paid with respect to the Non-Complaint Goods, at Customer’s sole discretion. Any further claims of whatever nature (e.g. , damages, compensation, etc.) are herewith expressly excluded, except with respect to Claims brought under
Article 13. HDPR shall have a right to remedy, through reprocessing, any Non-Compliance within a reasonable period of time, failing which Customer shall be entitled to the remedies set forth herein. HDPR shall
not do any reprocess work without Customer’s prior written approval, which shall not be withheld or delayed unreasonably. 
 12.2
UNLESS (A) IN CASE OF A PARTY’S GROSS NEGLIGENCE, WILLFUL MISCONDUCT OR FRAUD, (B) BREACH OF A PARTY’S REPRESENTATIONS, WARRANTIES AND COVENANTS HEREUNDER, (C) A PARTY’S INDEMNIFICATION OBLIGATION UNDER SECTION 13, (D)
A PARTY’S BREACH OF SECTION 16, OR (E) IN ANY CASE OF PERSONAL INJURY OR DEATHRESULTING FROM A PARTY’S GROSS NEGLIGENCE, INTENTIONAL MISCONDUCT OR FRAUD, WITH RESPECT TO EACH, EACH PARTY’S OVERALL LIABILITY UNDER THIS AGREEMENT
SHALL NOT EXCEED [**]) UNDER THIS AGREEMENT. 

  
 11 

 12.3 UNLESS RELATING TO (A) A PARTY’S GROSS NEGLIGENCE, INTENTIONAL MISCONDUCT OR
FRAUD, (B) A PARTY’S BREACH OF ITS REPRESENTATIONS, WARRANTIES OR COVENANTS, (C) A PARTY’S INDEMNIFICATION OBLIGATION UNDER SECTION 13, (D) A PARTY’S BREACH OF SECTION 16, OR (D) ANY CASE OF PERSONAL INJURY OR DEATH
CAUSED BY A PARTY’S GROSS NEGLIGENCE, INTENTIONAL MISCONDUCT OR FRAUD, WITH RESPECT TO EACH, NEITHER PARTY SHALL BE LIABLE FOR ANY CONSEQUENTIAL LOSSES AND DAMAGES, PUNITIVE DAMAGES, ANTICIPATED OR LOST PROFITS, BUSINESS INTERRUPTION,
INCIDENTAL DAMAGES, LOSS OF TIME, OR OTHER SIMILAR LOSSES IN CONNECTION WITH THIS AGREEMENT. 
 13 Indemnification  

13.1 Each Party shall indemnify the other Party and its representatives, consultants and Affiliates from and against any and all losses and
claims (including reasonable legal fees and other costs of defending any action) arising or resulting from Third Party Claims (as defined below) made against the other Party with respect to any death or personal injury arising as a result of the
gross negligence, fraud or intentional misconduct of such Party in connection, directly or indirectly, with this Agreement. 
 13.2 Customer
shall indemnify and hold HDPR and its Affiliates (and its and their officers, agents, employees, successors, subcontractors and assigns) (collectively, the “HDPR Indemnitees”) harmless from and against any and all losses and claims
(including reasonable legal fees and other costs of defending any action – each and all together referred to as the “Claims”) that an HDPR Indemnitee incurs as a result of any action brought by a Third Party (other than [**])
against an HDPR Indemnitee in connection with (a) Customer’s breach of this Agreement, (b) the gross negligence, fraud or intentional misconduct of a Customer Indemnitee or (c) the use, commercialisation, sale or transfer of the
Goods by Customer. The indemnification obligations under this Section 13.2 shall not apply to the extent that any such Third Party Claim is the result of (i) the gross negligence, fraud or intentional misconduct by an
HDPR Indemnitee, (ii) the breach of this Agreement by an HDPR Indemnitees (iii) any Claim for which HDPR is obligated to indemnify Customer pursuant to Section 13.3 or (iv) in any case of personal injury or death caused by the
negligent conduct, fraud or intentional misconduct of an HDPR Indemnitee. 
 13.3 HDPR shall indemnify and hold Customer and its Affiliates
(and its and their officers, agents, employees, successors, subcontractors and assigns) (collectively, the “Customer Indemnitees”) harmless from and against any and all losses and Claims that a Customer Indemnitee incurs as a result of any
action brought by a Third Party against a Customer Indemnitee in connection with (a) HDPR’s breach of this Agreement, (b) the gross negligence, fraud or intentional misconduct of an HDPR Indemnitee or (c) claims that the Goods or
Services infringe the intellectual property rights of a Third Party in violation of Section 9 h) above. The indemnification obligations under this Section 13.3 shall not apply to the extent that any such Third Party
Claim is the result of (i) the gross negligence, fraud or intentional misconduct by a Customer Indemnitee, (ii) the breach of this Agreement by a Customer Indemnitees (iii) any Claim for which Customer is obligated to indemnify HDPR
pursuant to Section 13.2 or (iv) in any case of personal injury or death caused by the negligent conduct, fraud or intentional misconduct of an Customer Indemnitee. 

13.4 The indemnifying Party shall defend, contest or otherwise protect against any Claims at its own cost and expense; provided
that the Party seeking indemnification regarding any such Claims gives written notice to the indemnifying Party promptly upon receiving notice of said Claims (but failure to give prompt written notice shall only relieve the
indemnifying Party of its obligations under Section 13.4 if, and in such event, only to the extent that, the indemnifying Party can demonstrate actual prejudice on account of such failure). The indemnified Party may, but
will not be obligated to, participate at its own expense in the defense of any Claim by counsel of its own choosing, but the indemnifying Party shall be entitled to control the defense, unless the indemnified Party has relieved

  
 12 

 
the indemnifying Party from liability with respect to the particular matter. The indemnifying Party shall have the right, after consultation with the indemnified Party, to resolve and settle any
such claims or suits; provided that, in no event may the indemnifying Party compromise or settle any such claim in a manner which admits fault or negligence on the part of the indemnified Party or includes injunctive
relief or includes the payment of money or other property by the indemnified Party without the prior written consent of the indemnified Party. The indemnifying Party shall not be responsible for any settlement or other disposition or agreement
reached in respect of any such action, claim or other matter unless the indemnifying Party shall have given its prior written consent in respect of such settlement, disposition or other agreement. The indemnified Party shall cooperate and provide
such assistance as the indemnifying Party may reasonably request in connection with the defence of the matter subject to indemnification. 
 14 Insurance

 Each Party shall have and maintain the insurance coverage that is required by Applicable Law. Each Party may self-insure its
liabilities under this Agreement and shall otherwise maintain such insurance as it, in its sole discretion, deems appropriate and necessary. 
 15
Intellectual Property 
 The Parties agree that (a) as between Customer and HDPR, each Party owns its respective Confidential
Information and (b) HDPR owns all rights in intellectual property related to Amanitin Toxin Constructs (subject to the licenses granted to Customer with respect thereto as set forth in the ERDOLA) and, subject to any rights of [**] thereto, all
rights in intellectual property related to the performance of Services. HDPR shall diligently pay all government fees required to maintain any of its patents used for the performance of Services under this Agreement. HDPR shall not knowingly use in
the performance of Services any intellectual property right of a Third Party to the extent such use would adversely impact or restrict Customer’s rights to freely exploit the Goods, except with the prior written consent of Customer. For the
avoidance of doubt, nothing in this Agreement shall be construed to grant Customer ownership of know-how, processes, techniques and innovations owned or controlled by HDPR or by [**], nor the right to use
deliverables provided hereunder to manufacture Amanitin Toxin Constructs without the previous completion of a GMP Full Manufacturing Technology Transfer as defined in the ERDOLA. 

16 Confidentiality 
 16.1 It is
contemplated that in the course of the performance of this Agreement each Party may, from time to time, disclose Confidential Information to the other and that HDPR and [**] may also disclose the confidential information of [**] to Customer in the
course of the performance of this Agreement, which shall be regarded as the Confidential Information of HDPR. Each Party agrees: 
  

	 	a)	 to keep and use in strict confidence all Confidential Information of the other Party that each Party acquires,
sees or is informed of as a direct or indirect consequence of this Agreement and to not, without the prior written consent of the other Party, disclose any such Confidential Information or recollections thereof to any Person other than its financial
or legal advisors, employees and contractors who are under an obligation of confidentiality on terms substantially similar to those set out in this Agreement, who have been informed of the confidential nature of the Confidential Information and who
reasonably require such information in the performance of their duties; 

  

	 	b)	 not to use, copy, duplicate, reproduce, translate or adapt, either directly or indirectly, any of the
Confidential Information of the other Party or any recollections thereof for any purpose other than the performance of each Party’s obligations under this Agreement, without the other Party’s prior written approval; and

  
 13 

	 	c)	 to take all reasonable steps (but never less than the degree of care such Party uses to protect its own
confidential information) to prevent material in its possession that contains or refers to Confidential Information of the other Party from being discovered, used or copied by Third Parties and that it shall use reasonable steps (but never less than
the degree of care such Party uses to protect its own confidential information) to protect and safeguard all Confidential Information of the other Party in its possession from all loss, theft or destruction. 

Upon the termination of this Agreement, each Party shall promptly return or destroy, at the disclosing Party’s election, all Confidential Information of
the disclosing Party; provided that the receiving Party may retain one copy of all such Confidential Information in its legal records for the purposes of ensuring compliance with this Agreement and the receiving Party may keep such
copies that may have been generated by automatic back-up systems. Notwithstanding anything in this Agreement to the contrary, any return or destruction of Confidential Information by the receiving Party is
subject to Applicable Law. 
 16.2 A Party receiving Confidential Information may, with the written consent of the disclosing Party,
disclose the disclosing Party’s Confidential Information also to Persons other than its financial and legal advisors, employees and contractors. 

16.3 The Parties agree that no press release, public announcement or publication regarding this Agreement or the relationship of the Parties
(except to the extent that it may be legally required), shall be made unless mutually agreed to in writing prior to the release or dissemination of any such press release, public announcement or publication. 

16.4 No provision of this Agreement shall be construed so as to preclude any disclosure of Confidential Information that is required, in the
reasonable opinion of the receiving Party’s legal advisors, to be disclosed by the receiving Party pursuant to Applicable Law or legal process, subpoena, warrant or court order. To the extent required by Applicable Law or legal process,
subpoena, warrant or court order, the receiving Party may disclose Confidential Information only to the extent required to comply with said Applicable Law or legal process, subpoena, warrant or court order; provided
that the receiving Party shall, if legally permitted and reasonably practicable, provide reasonable prior notice to the disclosing Party so as to allow the disclosing Party to take steps to oppose or limit the required disclosure,
at the disclosing Party’s sole cost and expense. 
 16.5 Unless otherwise agreed by the Parties in writing, the obligations of the
Parties relating to Confidential Information set out in this Article 16 shall survive the termination or expiration of this Agreement for a period of [**] thereafter; provided that such obligations will
survive with respect to any Confidential Information that constitutes a trade secret for so long as such Confidential Information remains a trade secret. 

17 Force majeure 
 17.1 Neither Party
shall be held liable for any failure in performance of any part of this Agreement or any breach of contract resulting from force majeure events, including but not limited to fire, flood, explosion, war, strike, embargo, shortages, acts of God,
terrorism, riots or similar causes. If a Party is affected by an event of force majeure, it will forthwith notify the other Party of the nature and extent of such force majeure event and the Parties will enter into bona fide discussions with a view
to alleviating its effects and to agreeing such alternative arrangements as may be fair, reasonable and practicable. The Party affected by a force majeure event is under obligation to give full particulars thereof and to use its best efforts to
minimize the effect of occurrence and to take the necessary remedial measures. 

  
 14 

 17.2 If as a result of force majeure events, performance of the Agreement, in whole or
material part, is suspended for more than [**] or [**], either Party shall have the right to terminate the Agreement or any affected Work Order by giving written notice to that effect to the other Party. 

18 General provisions 
 18.1 No course of
dealing or failure of either Party to strictly enforce any term, right or condition of this Agreement shall be construed as a waiver of that term, right or condition. 

18.2 Should one of the provisions of this Agreement or of any additional stipulations agreed upon be or become invalid, the validity of the
remaining conditions and stipulations shall not be affected thereby. Parties shall use their best endeavours to replace the invalid provisions with a valid provision with respect to the same subject matter. 

18.3 This Agreement constitutes the entire agreement and understandings (oral and written) between the Parties relating to the subject matter
hereof and supersede all previous oral and written communications between the Parties with respect hereof. 
 18.4 No modification,
alteration or amendment to this Agreement, including without limitation this Section 18.4, shall be of any force or effect unless done in writing with the express reference to the Sections of the Agreement being modified, altered or amended
and signed by duly authorized representative of both Parties. 
 18.5 This Agreement shall be binding upon and shall inure to the benefit of
the Parties hereto and their successors and permitted assigns. The provisions set forth in the ERDOLA with regard to Assignment (as defined therein) shall also apply to this Agreement (except with respect to a
Non-GMP Partial Manufacturing Technology Transfer, a Non-GMP Full Manufacturing Technology Transfer or a GMP Full Manufacturing Technology Transfer (each as defined in
the ERDOLA)). 
 18.6 The Parties hereto are independent contractors and nothing contained in this Agreement shall be deemed or construed to
create a partnership, joint venture, employment, franchise, agency or fiduciary relationship between the Parties. 
 18.7 The table of
contents and headings are for convenience only, and are to be of no force or effect in construing or interpreting any of the provisions of this Agreement. Unless the context otherwise clearly requires or otherwise specified, whenever used in this
Agreement: (a) the word “including” and words of similar import shall mean “including, without limitation”; (b) the words “hereof,” “herein,” “hereby” and derivative or similar words refer to
this Agreement; (c) whenever the word “or” is used in this Agreement, it shall not be deemed to be exclusive; (d) all references to the word “will” are interchangeable with the word “shall” and shall be
understood to be imperative or mandatory in nature; and (e) all words used in this Agreement shall be construed to be of such gender or number, as the circumstances require. 

18.8 This Agreement may be executed in multiple counterparts, each of which shall be deemed an original and all of which together shall
constitute one and the same instrument. Any PDF or facsimile copy of this Agreement, or of any counterpart, shall be deemed the equivalent of an original. 

  
 15 

 19 Notices 

19.1 Any official notice required under this Agreement shall be in writing and shall specifically refer to this Agreement. Notices shall be
sent via one of the following means and will be effective: (a) on the date of delivery, if delivered and handed over in person; (b) if sent by email (with delivery confirmed) (i) on the date of receipt, provided,
however, that the email was received by recipient on a Business Day at his domicile between 00.00 and 17.00 his time zone; (ii) the next Business Day following receipt, if the email was received by recipient outside a
Business Day at his domicile or between 17.00 and 24.00 his time zone; or (c) seventy two (72) hours after postage, if sent by private express courier or by first class certified mail, return receipt requested. Any notice sent via email
shall be followed as soon as reasonably possible by a copy of such notice by private express courier or by first class mail. 
 19.2 Notices
shall be sent to the other Party at the addresses set forth below. Either Party may change its addresses or addressees for purposes of this Article 19 by sending written notice to the other Party. 

 

			
	 If to HDPR, to:
	  	 Heidelberg Pharma Research GmbH
 Attn: Business
Development
 Schriesheimer Strasse 101
 68526 Ladenburg

Germany
 [**]

[**]

		
	 and:
	  	 Attn: Legal Department
 [**]

[**]

		
	 If to Customer, to:
	  	 Magenta Therapeutics, Inc.
 100 Technology
Square, 5th Floor
 Cambridge, MA 02139 USA

[**]
 [**]

 or to such other address as the Party to whom notice is to be given may have furnished to the other Party in
writing in accordance herewith. Any such notice shall be deemed delivered on the date received. 
 19.3 The provisions of this Article
19 shall not be applicable for the day-to-day communication between the Parties. 

20 Term and termination 
 20.1 This
Agreement shall be effective as of and commence on the Effective Date and continue in full force and effect for an indefinite term unless terminated pursuant to Sections 20.2, 20.3 or 20.4. 

20.2 (a) Customer may terminate this Agreement or any Work Order at any time and for any reason upon at least sixty (60) calendar days
written notice. (b) Either Party may terminate this Agreement if the corresponding agreement between HDPR and [**] is terminated. 

  
 16 

 20.3 Either Party may terminate this Agreement upon written notice to the other Party with
immediate effect if the other Party makes a general assignment for the benefit of creditors or if a petition in bankruptcy or under any insolvency law is filed by or against the other Party and such petition is not dismissed within [**] after it has
been filed. 
 20.4 Either Party may terminate this Agreement (in its entirety, for a material breach that relates to this Agreement in its
entirety) or a Work Order (only with respect to a Work Order, if a material breach solely relates to such Work Order) upon written notice to the other Party with immediate effect if the other Party has committed a material breach of this Agreement,
a Work Order, or the Quality Agreement, and: 
  

	 	(i)	 the breach is not cured within [**] after written notice of such breach has been provided to the breaching
Party; or 

  

	 	(ii)	 if the breach is of a type that cannot be cured within [**], but the breaching Party has promptly commenced and
is diligently pursuing remediation of such breach following the breaching Party receiving written notice of such breach, then only if such breach has not been cured within [**] after written notice of such breach has been provided to the breaching
Party. 

 20.5 In case of termination of a Service by Customer, Customer shall pay to HDPR the fees set forth in the
corresponding Work Order. 
 20.6 Notwithstanding the foregoing, in case of a termination by Customer pursuant to Sections 17.2, 20.3
or 20.4, or by either Party pursuant to Section 20.2(b), then Section 20.5 shall not apply. 
 20.7 Upon termination of this
Agreement, all rights and obligations of the Parties under this Agreement shall terminate and be of no further force or effect. No termination of this Agreement will relieve the parties of any obligation accruing prior to such termination. In
addition, the following Sections shall survive termination of this Agreement: 2.5; 5; 6; 8 to 19 (included); 20.5; 20.6, 20.7 and 21. 
 21 Applicable
law and jurisdiction 
 21.1 This Agreement shall be construed, interpreted, governed and enforced exclusively in accordance with the
substantive Swiss law except as for its conflict of law rules, which would refer to another applicable law. The application of the Convention of the United Nations of April 11, 1980 on Contract for the International Sale of Goods is
hereby expressly excluded. 
 21.2 The Parties shall try to resolve any disputes arising out of or in connection with this Agreement
amicably through good faith negotiations. In the event that such attempts should fail within [**] from the first negotiation, the dispute shall be exclusively and finally resolved by the Civil-Court of Basel-Stadt, Switzerland
(“Zivilgericht Basel-Stadt”). This shall not limit the right to appeal in Switzerland. 
 [Remainder Intentionally
Blank.] 

  
 17 

 In WITNESS OF THE FOREGOING, the Parties have caused their authorized representatives to execute this
Agreement as of the Effective Date. 
  

							
	Heidelberg Pharma Research GmbH:	  	Magenta Therapeutics, Inc.:
				
	By:	  	 /s/ Dr. Jan Schmidt-Brand
	  	By:	  	 /s/ Jason Gardner

	Name:	  	Dr. Jan Schmidt-Brand	  	Name:	  	Jason Gardner
		  	Chief Executive Officer	  		  	
				
	Date:	  	23. MAI 2019	  	Date: 	  	6/3/19
				
	By:	  	 ppa. /s/ Prof. Dr. Andreas Pahl
	  	By:	  	 /s/ Christina Isacson

	Name:	  	Prof. Dr. Andreas Pahl	  	Name:	  	Christina Isacson
		  	Chief Scientific Officer	  		  	
				
	Date:	  	23. MAI 2019	  	Date: 	  	6/3/19

 ANNEX 3.8 

[**]EX-10.12

 EXHIBIT 10.12 

AMENDED AND RESTATED 

EMPLOYMENT AGREEMENT 
 This
Amended and Restated Employment Agreement (“Agreement”) is made by and between Magenta Therapeutics, Inc., a Delaware corporation (the “Company”), and Jason Gardner, D.Phil. (the “Executive”) and is effective as
March 3, 2022. 
 WHEREAS, the Executive is currently serving as the Company’s Chief Executive Officer and President, and
possesses certain experience and expertise that qualify the Executive to provide the direction and leadership required by the Company and its affiliates; 

WHEREAS, the Company and the Executive are party to an Employment Agreement dated as of June 25, 2018 (the “Original
Agreement”); and 
 WHEREAS, the Company and the Executive wish to amend and restate the Original Agreement in accordance with the
terms and conditions set forth in this Agreement. 
 NOW, THEREFORE, in consideration of the mutual covenants and agreements herein
contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: 
  

	 	1.	 Employment. 

(a)    Term. The Company and the Executive desire to continue their employment relationship pursuant to this
Agreement as of the Effective Date and continuing in effect until terminated by either party in accordance with this Agreement (the “Term”). The Executive’s employment with the Company will continue to be “at will,” meaning
that the Executive’s employment may be terminated by the Company or the Executive at any time and for any reason subject to the terms of this Agreement. 

(b)    Position and Duties. During the Term, the Executive shall serve as the President and Chief Executive Officer
of the Company and shall have powers and duties that may from time to time be prescribed by the Board of Directors of the Company (the “Board”). The Executive shall devote his full working time and efforts to the business and
affairs of the Company. Notwithstanding the foregoing, the Executive may serve on up to two other boards of directors, with the prior written approval of the Board, or engage in
not-for-profit, charitable or other community activities as long as the foregoing does not, individually or in the aggregate, materially interfere with the
Executive’s performance of his duties to the Company as provided in this Agreement. The Executive reaffirms that he has no contractual commitments or other legal obligations that would prohibit him from fully performing his duties for the
Company. 
 (c)    Regular Place of Employment. The Executive’s regular place of work will be at Magenta
Therapeutics, Inc., which is currently located at 100 Technology Square, Cambridge, MA 02139, provided that the Executive may be required to travel from time to time, consistent with business needs. 

	 	2.	 Compensation and Related Matters. 

(a)    Base Salary. The Executive’s annual base salary shall be $565,000, which is subject to review and
redetermination by the Board. The base salary in effect at any given time is referred to herein as “Base Salary.” The Base Salary shall be payable in a manner that is consistent with the Company’s usual payroll practices for senior
executives. 
 (b)    Incentive Compensation. During the Term, the Executive shall be eligible to receive cash
incentive compensation as determined by and in the sole discretion of the Board or the Compensation Committee from time to time. The Executive’s target annual incentive compensation shall be fifty-five percent (55%) of his Base Salary, as may
be redetermined from time to time (the “Target Incentive Compensation”). To earn incentive compensation, the Executive must be employed by the Company on the day such incentive compensation is paid. 

(c)    Expenses. The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses
incurred by him during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its senior executive officers. 

(d)    Other Benefits. During the Term, the Executive shall be entitled to continue to participate in or receive
benefits under the Company’s employee benefit plans in effect from time to time, including paid sick time under applicable law, subject to the terms of such plans and to the Company’s ability to amend, modify, replace or terminate such
plans and programs. 
 (e)    Vacations. During the Term, the Executive shall be entitled to take paid vacation
in accordance with the Company’s vacation policy, as may be in effect from time to time. The Executive shall also be entitled to all paid holidays given by the Company to its executives. 

(f)    Equity. The equity awards held by the Executive shall be governed by the terms and conditions of the
Company’s applicable equity incentive plan(s) and the applicable award agreement(s) governing the terms of such equity awards held by the Executive (collectively, the “Equity Documents”); provided, however, and notwithstanding
anything to the contrary in the Equity Documents, Section 6(a)(ii) of this Agreement shall apply in the event of a termination by the Company without Cause or by the Executive for Good Reason in either event within the Change in Control Period
(as such terms are defined below). 
 3.    Termination. During the Term, the Executive’s employment
hereunder may be terminated without any breach of this Agreement under the following circumstances: 

(a)    Death. The Executive’s employment hereunder shall terminate upon his death. 

(b)    Disability. The Company may terminate the Executive’s employment if he is disabled and unable to
perform the essential functions of the Executive’s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any
12-month period. If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive’s then existing position or
positions with or without reasonable 

  
 2 

 
accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the Executive
or the Executive’s guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of the issue.
The Executive shall cooperate with any reasonable request of the physician in connection with such certification. If such question shall arise and the Executive shall fail to submit such certification, the Company’s determination of such issue
shall be binding on the Executive. Nothing in this Section 3(b) shall be construed to waive the Executive’s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. §2601
et seq. and the Americans with Disabilities Act, 42 U.S.C. §12101 et seq. 
 (c)    Termination by
Company for Cause. The Company may terminate the Executive’s employment hereunder for Cause. For purposes of this Agreement, “Cause” shall mean: (i) the Executive’s dishonest statements or acts with respect to the
Company or any affiliate of the Company, or any current or prospective customers, suppliers vendors or other third parties with which such entity does business; (ii) the Executive’s commission of (A) a felony or (B) any
misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) the Executive’s failure to perform his assigned duties and responsibilities to the reasonable satisfaction of the Company which failure continues, in the reasonable
judgment of the Company, thirty (30) or more days after written notice has been given to the Executive by the Company reasonably describing such failure; (iv) the Executive’s gross negligence, willful misconduct or insubordination
with respect to the Company or any affiliate of the Company; or (v) the Executive’s material violation of any provision of any agreement(s) between the Executive and the Company relating to noncompetition, nonsolicitation, nondisclosure,
nondisparagement and/or assignment of inventions. 
 (d)    Termination Without Cause. The Company may terminate
the Executive’s employment hereunder at any time without Cause. Any termination by the Company of the Executive’s employment under this Agreement which does not constitute a termination for Cause under Section 3(c) and does not result
from the death or disability of the Executive under Section 3(a) or (b) shall be deemed a termination without Cause. 

(e)    Termination by the Executive. The Executive may terminate his employment hereunder at any time for any
reason, including but not limited to Good Reason. For purposes of this Agreement, “Good Reason” shall mean that the Executive has complied with the “Good Reason Process” (hereinafter defined) following the occurrence of any of
the following events: (i) a material diminution in the Executive’s responsibilities, authority or duties; (ii) a material diminution in the Executive’s Base Salary except for across-the-board salary reductions based at least in part on the Company’s financial performance similarly affecting all or substantially all senior management employees of the Company; (iii) a
material change in the geographic location at which the Executive provides services to the Company; or (iv) the material breach of this Agreement by the Company. “Good Reason Process” shall mean that (i) the Executive reasonably
determines in good faith that a “Good Reason” condition has occurred; (ii) the Executive notifies the Company in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition;
(iii) the Executive cooperates in good faith with the Company’s efforts, for a period not less than thirty (30) days following such notice (the “Cure Period”), to remedy the condition; (iv) notwithstanding such efforts,
the Good Reason 

  
 3 

 
condition continues to exist; and (v) the Executive terminates his employment within 60 days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure
Period, Good Reason shall be deemed not to have occurred. 
 If the Executive’s employment with the Company is terminated for any
reason, the Company shall pay or provide to the Executive (or to his authorized representative or estate) (i) any Base Salary earned through the Date of Termination, unpaid expense reimbursements (subject to, and in accordance with,
Section 2(c) of this Agreement) on or before the time required by law but in no event more than thirty (30) days after the Executive’s Date of Termination; (ii) accrued but unused vacation and personal days (if applicable and in
accordance with Company policy and applicable law); and (iii) any vested benefits the Executive may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in
accordance with the terms of such employee benefit plans (collectively, the “Accrued Benefits”). 
  

	 	4.	 Notice and Date of Termination. 

(a)    Notice of Termination. Except for termination as specified in Section 3(a), any termination of the
Executive’s employment by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a “Notice of Termination” shall mean a
notice which shall indicate the specific termination provision in this Agreement relied upon. 
 (b)    Date of
Termination. “Date of Termination” shall mean: (i) if the Executive’s employment is terminated by his death, the date of his death; (ii) if the Executive’s employment is terminated on account of disability under
Section 3(b) or by the Company for Cause under Section 3(c), the date on which Notice of Termination is given; (iii) if the Executive’s employment is terminated by the Company under Section 3(d), the date on which a Notice
of Termination is given; (iv) if the Executive’s employment is terminated by the Executive under Section 3(e) without Good Reason, 30 days after the date on which a Notice of Termination is given, and (v) if the Executive’s
employment is terminated by the Executive under Section 3(e) for Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period. Notwithstanding the foregoing, in the event that the Executive gives a Notice of
Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement. 

5.    Compensation Upon Termination by the Company without Cause or by the Executive for Good Reason Outside the Change
in Control Period. During the Term, if the Executive’s employment is terminated by the Company without Cause as provided in Section 3(d), or the Executive terminates his employment for Good Reason as provided in Section 3(e), each
outside of the Change in Control Period (as defined below), then the Company shall pay the Executive his Accrued Benefit. In addition, subject to (i) the Executive signing a separation agreement and release in a form and manner satisfactory to
the Company, which shall include, without limitation, a general release of claims against the Company and all related persons and entities, a reaffirmation of all of the Executive’s Continuing Obligations (as defined below) and,
in the Company’s sole discretion, a one year post- employment noncompetition covenant, and shall 

  
 4 

 
provide that if the Executive breaches any of the Continuing Obligations, all payments of the Severance Amount shall immediately cease (the “Separation Agreement and Release”), and
(ii) the Separation Agreement and Release becoming irrevocable, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement and Release): 

(a)    the Company shall pay the Executive an amount equal to the sum of (A) one (1) times the
Executive’s Base Salary plus (B) a pro-rata portion of the Executive’s Target Incentive Compensation, based on the number of days that have passed as of the Date of Termination in the year in
which the Date of Termination occurs (the “Severance Amount”). Notwithstanding the foregoing, if the Executive breaches any of the provisions contained in Section 8 of this Agreement or the Restrictive Covenants Agreement, all
payments of the Severance Amount shall immediately cease; and 
 (b)    if the Executive was participating in the
Company’s group health plan immediately prior to the Date of Termination and elects COBRA health continuation, then the Company shall pay the monthly employer COBRA premium for the same level of group health coverage as in effect for the
Executive on the Date of Termination until the earliest of the following: (i) the twelve (12) month anniversary of the Date of Termination; (ii) the Executive’s eligibility for group health coverage through other employment; or
(iii) the end of the Executive’s eligibility under COBRA for continuation coverage for health care. If the payment of any COBRA or health insurance premiums by Company on behalf of Executive as described herein would otherwise violate any
applicable nondiscrimination rules or cause the reimbursement of claims to be taxable under the Patient Protection and Affordable Care Act of 2010, together with the Health Care and Education Reconciliation Act of 2010 (collectively, the
“Healthcare Acts”) or Section 105(h) of the Code, the COBRA premiums paid by the Company shall be treated as taxable payments (subject to customary and required taxes and employment-related deductions) and be subject to imputed
income tax treatment to the extent necessary to eliminate any discriminatory treatment or taxation under the Healthcare Acts or Section 105(h) of the Code. If Company determines in its sole discretion that it cannot provide the COBRA benefits
described herein under Company’s health insurance plan without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), Company shall in lieu thereof provide to Executive a
taxable lump-sum payment in an amount equal to the sum of the monthly (or then remaining) COBRA premiums that Executive would be required to pay to maintain Executive’s group health insurance coverage in
effect on the separation date for the remaining portion of the period for which Executive shall receive the payments described in this Section 5(b). 

(c)    The amounts payable under this Section 5 shall be paid out in substantially equal installments in accordance
with the Company’s payroll practice, with the first installment commencing within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and
ends in a second calendar year, the Severance Amount shall begin to be paid in the second calendar year by the last day of such 60-day period; provided, further, that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury
Regulation Section 1.409A-2(b)(2). 

  
 5 

 6.    Compensation Upon Termination by the Company without Cause or
by the Executive for Good Reason within the Change in Control Period. The provisions of this Section 6 shall apply in lieu of, and expressly supersede, the provisions of Section 5 regarding severance pay and benefits upon a termination
by the Company without Cause or by the Executive for Good Reason if such termination of employment occurs during the three (3) months before through twelve (12) months after the occurrence of the first event constituting a Change in
Control (such period, the “Change in Control Period”). These provisions shall terminate and be of no further force or effect beginning twelve (12) months after the occurrence of a Change in Control. 

(a)    Change in Control. If during the Change in Control Period the Executive’s employment is terminated by
the Company without Cause as provided in Section 3(d) or the Executive terminates his employment for Good Reason as provided in Section 3(e), then, subject to the signing of the Separation Agreement and Release by the Executive and the
Separation Agreement and Release becoming irrevocable, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement and Release): 

(i)    the Company shall pay the Executive a lump sum in cash in an amount equal to the sum of (A) 1.5
times the Executive’s current Base Salary (or the Executive’s Base Salary in effect immediately prior to the Change in Control, if higher) plus (B) one hundred and fifty percent (150%) of the Executive’s Target Incentive
Compensation (the “Change in Control Payment”); and 
 (ii)    notwithstanding anything to the
contrary in any applicable option agreement or stock-based award agreement, all time-based stock options and other time-based stock-based awards held by the Executive shall immediately accelerate and become fully vested and exercisable or
nonforfeitable as of the Date of Termination; and 
 (iii)    if the Executive was participating in the
Company’s group health plan immediately prior to the Date of Termination and elects COBRA health continuation, then the Company shall pay the full monthly COBRA premium for the same level of group health coverage as in effect for the Executive
on the Date of Termination until the earliest of the following: (i) the 18-month anniversary of the Date of Termination; (ii) the Executive’s eligibility for group health coverage through other employment; or (iii) the end of the
Executive’s eligibility under COBRA for continuation coverage for health care. If the payment of any COBRA or health insurance premiums by Company on behalf of Executive as described herein would otherwise violate any applicable
nondiscrimination rules or cause the reimbursement of claims to be taxable under the Healthcare Acts or Section 105(h) of the Code, the COBRA premiums paid by the Company shall be treated as taxable payments (subject to customary and required
taxes and employment-related deductions) and be subject to imputed income tax treatment to the extent necessary to eliminate any discriminatory treatment or taxation under the Healthcare Acts or Section 105(h) of the Code. If Company determines
in its sole discretion that it cannot provide the COBRA benefits described herein under Company’s health insurance plan without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service
Act), Company shall in lieu thereof provide to Executive a taxable lump-sum payment in an amount equal to the sum of the monthly (or then remaining) 

  
 6 

 
COBRA premiums that Executive would be required to pay to maintain Executive’s group health insurance coverage in effect on the separation date for the remaining portion of the period for
which Executive shall receive the payments described in this Section 6(a). 
 The amounts payable under this Section 6(a) shall be paid or
commence to be paid within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payment shall be paid or
commence to be paid in the second calendar year by the last day of such 60-day period. 

(b)    Additional Limitation. 

(i)    Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any
compensation, payment or distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with
Section 280G of the Code and the applicable regulations thereunder (the “Aggregate Payments”), would be subject to the excise tax imposed by Section 4999 of the Code, then the Aggregate Payments shall be reduced (but not below
zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which the Executive becomes subject to the excise tax imposed by Section 4999 of the Code; provided that such reduction shall only occur if it would
result in the Executive receiving a higher After Tax Amount (as defined below) than the Executive would receive if the Aggregate Payments were not subject to such reduction. In such event, the Aggregate Payments shall be reduced in the following
order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section 280G of the Code: (1) cash payments not
subject to Section 409A of the Code; (2) cash payments subject to Section 409A of the Code; (3) equity-based payments and acceleration; and (4) non-cash forms of benefits; provided
that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. §1.280G-1, Q&A-24(b) or
(c) shall be reduced before any amounts that are subject to calculation under Treas. Reg. §1.280G-1, Q&A-24(b) or (c). 

(ii)    For purposes of this Section 6(b), the “After Tax Amount” means the amount of the
Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on the Executive as a result of the Executive’s receipt of the Aggregate Payments. For purposes of determining the After Tax Amount, the Executive
shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal
rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. 

(iii)    The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to
Section 6(b)(i) shall be made by a nationally recognized accounting firm selected by the Company (the “Accounting Firm”), which shall provide detailed supporting calculations both to the Company and the Executive within 15

  
 7 

 
business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive. Any determination by the Accounting Firm shall be
binding upon the Company and the Executive. 
 (b)    Definitions. For purposes of this Section 6,
“Change in Control” shall mean any of the following: 
 (i)    any “person,” as such
term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the “Act”) (other than the Company, any of its subsidiaries, or any trustee, fiduciary or other person or entity holding securities under any
employee benefit plan or trust of the Company or any of its subsidiaries), together with all “affiliates” and “associates” (as such terms are defined in Rule 12b-2 under the Act) of such
person, shall become the “beneficial owner” (as such term is defined in Rule 13d-3 under the Act), directly or indirectly, of securities of the Company representing 50 percent or more of the
combined voting power of the Company’s then outstanding securities having the right to vote in an election of the Board (“Voting Securities”) (in such case other than as a result of an acquisition of securities directly from the
Company); or 
 (ii)    the date a majority of the members of the Board is replaced during any 12-month period by directors whose appointment or election is not endorsed by a majority of the members of the Board before the date of the appointment or election; or 

(iii)    the consummation of (A) any consolidation or merger of the Company where the stockholders of
the Company, immediately prior to the consolidation or merger, would not, immediately after the consolidation or merger, beneficially own (as such term is defined in Rule 13d-3 under the Act), directly or
indirectly, shares representing in the aggregate more than 50 percent of the voting shares of the Company issuing cash or securities in the consolidation or merger (or of its ultimate parent corporation, if any), or (B) any sale or other
transfer (in one transaction or a series of transactions contemplated or arranged by any party as a single plan) of all or substantially all of the assets of the Company. 

Notwithstanding the foregoing, a “Change in Control” shall not be deemed to have occurred for purposes of the foregoing clause
(i) solely as the result of an acquisition of securities by the Company which, by reducing the number of shares of Voting Securities outstanding, increases the proportionate number of Voting Securities beneficially owned by any person to
50 percent or more of the combined voting power of all of the then outstanding Voting Securities; provided, however, that if any person referred to in this sentence shall thereafter become the beneficial owner of any additional shares of Voting
Securities (other than pursuant to a stock split, stock dividend, or similar transaction or as a result of an acquisition of securities directly from the Company) and immediately thereafter beneficially owns 50 percent or more of the combined
voting power of all of the then outstanding Voting Securities, then a “Change in Control” shall be deemed to have occurred for purposes of the foregoing clause (i). 

  
 8 

 7.    Section 409A. 

(a)    Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive’s separation from
service within the meaning of Section 409A of the Code, the Company determines that the Executive is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit
that the Executive becomes entitled to under this Agreement on account of the Executive’s separation from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to
Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one
day after the Executive’s separation from service, or (B) the Executive’s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a
catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the
installments shall be payable in accordance with their original schedule. 
 (b)    All
in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement. All
reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement
in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for
another benefit. 
 (c)    To the extent that any payment or benefit described in this Agreement constitutes “non-qualified deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Executive’s termination of employment, then such payments
or benefits shall be payable only upon the Executive’s “separation from service.” The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury
Regulation Section 1.409A-1(h). 
 (d)    The parties intend that this
Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so
that all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation
Section 1.409A-2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all
related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. 

  
 9 

 (e)    The Company makes no representation or warranty and shall have no
liability to the Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.

 8.    Restrictive Covenants. 

(a)    Restrictive Covenants Agreement. The terms of the Employee Confidentiality and Assignment Agreement dated
June 12, 2016, between the Company and the Executive, as modified by the Original Agreement and reaffirmed herein (the “Restrictive Covenants Agreement”), continues to be in full force and effect. The Executive agrees that the term
“Company,” as used in the Restrictive Covenants Agreement, shall mean the Company, its subsidiaries and other affiliates, and its and their successors and assigns. The Executive hereby reaffirms the terms of the Restrictive Covenants
Agreement, and as modified by the Original Agreement and reaffirmed in Section 8(b) below, as material terms of this Agreement and agrees and acknowledges that such terms are incorporated by reference in this Agreement. 

(b)    Noncompetition and Nonsolicitation. This Section 8(b) amends, restates, and supersedes Section 8
of the Restrictive Covenants Agreement. 

(i)    Non-Solicitation. In order to protect the
Company’s proprietary information and good will, both during Executive’s employment and for a period of one (1) year following the date of the cessation of Executive’s employment with the Company for any reason, (the
“Restricted Period”), the Executive will not either alone or in association with others: 
 (1)
    solicit, induce or attempt to induce, any employee or independent contractor of the Company to terminate his/her employment or other engagement with the Company; 

(2)     solicit, hire, or recruit or attempt to hire as an employee, or engage or attempt to engage as an
independent contractor, any person who was employed or otherwise engaged by the Company at any time during the term of my employment with the Company; provided that this clause (2) shall not apply to the recruitment or hiring or other
engagement of any individual whose employment or other engagement with the Company has been terminated for a period of six (6) months or longer, or was terminated at the discretion of the Company and not by such person; provided,
further, that subsection (b) shall not apply to individuals who are employed by the Company or a subsequent employer, in California; or 

(3)    solicit, divert or take away, or attempt to divert or take away, the business or patronage of any of
the clients, customers, or business partners of the Company that were contacted, solicited, or served by the Company during the twelve (12) month period prior to the termination or cessation of my employment with the Company; provided,
however, the foregoing shall not apply to services rendered by me in California after the date my employment by the Company terminates. 

  
 10 

(ii)    Non-Compete. 

(1)    Executive will not without the prior written approval of an executive officer of the Company, engage
or assist others in engaging in any business or enterprise (whether as owner, partner, officer, director, employee, consultant, investor, lender or otherwise, except as the holder of not more than 1% of the outstanding stock of a publicly-held
company) that is competitive with the Company’s business by engaging in the research, development, manufacture, marketing, distribution, sale or commercialization of any products that the Company is, at the time of my termination, so engaged
in, or, to my knowledge, planning to engage in or otherwise actively evaluating, or any alternatives to such products. This Section 8(b)(ii)(1) shall be effective (i) during the term of my employment by the Company, and (ii) for a
period of one (1) year after my employment with the Company ends for any reason, provided that the Company makes a one-time payment to me of $5,000 within fifteen (15) calendar days after the date of
my termination. 
 (2)    Executive understands and agrees that payment set forth in
Section 8(b)(ii)(1) above (i) has been mutually agreed upon by Executive and the Company; (ii) is fair and reasonable; and (iii) is sufficient in exchange for my obligations set forth in this paragraph. 

(3)    Executive understands and agrees, at or around the time Executive’s employment with the Company
ends, and in the Company’s sole discretion, the Company may waive the Executive’s obligations in this Section 8(b)(ii)(1), in which case the Company will not be required to provide me with any of the payments set forth in
Section 8(b)(ii)(1) above. 
 The Executive acknowledges and agrees that if he violates any of the provisions of this
Section 8(b), the running of the Restricted Period will be extended by the time during which the Executive engages in such violation(s). The Executive understands that the restrictions set forth in this Section 8(b) are intended to protect
the Company’s interest in its confidential information and established employee, customer and supplier relationships and goodwill, and agrees that such restrictions are reasonable and appropriate for this purpose. For purposes of this
Agreement, the obligations in this Section 8 and those that arise in the Restrictive Covenants Agreement and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be
referred to as the “Continuing Obligations.” 
 (c)    Third-Party Agreements and Rights. The Executive
hereby confirms that the Executive is not bound by the terms of any agreement with any previous employer or other party which restricts in any way the Executive’s use or disclosure of information or the Executive’s engagement in any
business. The Executive represents to the Company that the Executive’s execution of this Agreement, the Executive’s employment with the Company and the performance of the Executive’s proposed duties for the Company will not violate
any obligations the Executive may have to any such previous employer or other party. In the Executive’s work for the Company, the Executive will not disclose or make use of any information in violation of any agreements with or rights of any
such previous employer or other party, and the Executive will not bring to the premises of the Company any copies or other tangible embodiments of non-public information belonging to or obtained from any such
previous employment or other party. 

  
 11 

 (d)    Litigation and Regulatory Cooperation. During and after
the Executive’s employment, the Executive shall cooperate fully with the Company in the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to
events or occurrences that transpired while the Executive was employed by the Company. The Executive’s full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to
prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During and after the Executive’s employment, the Executive also shall cooperate fully with the Company in connection with any
investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company. The Company shall reimburse the
Executive for any reasonable out-of-pocket expenses incurred in connection with the Executive’s performance of obligations pursuant to this Section 8(d). 

(e)    Injunction. The Executive agrees that it would be difficult to measure any damages caused to the Company
which might result from any breach by the Executive of the promises set forth in this Section 8, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly, the Executive agrees that if the Executive
breaches, or proposes to breach, any portion of this Agreement, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to restrain any such breach without showing or
proving any actual damage to the Company. 
 (f)    Protected Disclosures and Other Protected Actions. Nothing in
this Agreement shall be interpreted or applied to prohibit the Executive from making any good faith report to any governmental agency or other governmental entity (a “Government Agency”) concerning any act or omission that the Executive
reasonably believes constitutes a possible violation of federal or state law or making other disclosures that are protected under the anti-retaliation or whistleblower provisions of applicable federal or state law or regulation. In addition, nothing
contained in this Agreement limits the Executive’s ability to communicate with any Government Agency or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including the Executive’s
ability to provide documents or other information, without notice to the Company. In addition, for the avoidance of doubt, pursuant to the federal Defend Trade Secrets Act of 2016, the Executive shall not be held criminally or civilly liable under
any federal or state trade secret law or under this Agreement or the Restrictive Covenants Agreements for the disclosure of a trade secret that (a) is made (i) in confidence to a federal, state, or local government official, either
directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing
is made under seal. 
 9.    Consent to Jurisdiction. The parties hereby consent to the jurisdiction of the
Superior Court of the Commonwealth of Massachusetts and the United States District Court for the District of Massachusetts. Accordingly, with respect to any such court action, the Executive (a) submits to the personal jurisdiction of such
courts; (b) consents to service of process; and (c) waives any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process. 

  
 12 

 10.    Representations and Warranties. By signing this agreement,
Executive represents that Executive has not been debarred under Subsection (a) or (b) of Section 306 of the United States Federal Food, Drug, and Cosmetic Act (21 U.S. C. 335a); and is not on any FDA clinical investigator enforcement lists
(including the (i) Disqualified/Totally Restricted List, (ii) Restricted List and (iii) Adequate Assurances List). 

11.    Integration. This Agreement constitutes the entire agreement between the parties with respect to
compensation, severance pay, benefits and accelerated vesting and supersedes in all respects all prior agreements between the parties concerning such the subject matter hereof, including without limitation the Original Agreement or any offer letter,
employment agreement or severance agreement relating to the Executive’s employment relationship with the Company and/or the ending of that employment relationship. Notwithstanding the foregoing, the Restrictive Covenants Agreement (as modified
herein), the Equity Documents, and any other agreement relating to confidentiality, noncompetition, nonsolicitation or assignment of inventions shall not be superseded by this Agreement and the Executive acknowledges and agrees that any such
agreements remain in full force and effect. 
 12.    Withholding. All payments made by the Company to the
Executive under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law. 

13.    Enforceability. If any portion or provision of this Agreement (including, without limitation, any portion or
provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other
than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law. 

14.    Survival. The provisions of this Agreement shall survive the termination of this Agreement and/or the
termination of the Executive’s employment to the extent necessary to effectuate the terms contained herein. 

15.    Waiver. No waiver of any provision hereof shall be effective unless made in writing and signed by the
waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be
deemed a waiver of any subsequent breach. 
 16.    Notices. Any notices, requests, demands and other
communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to
the Executive at the last address the Executive has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the Board. 

  
 13 

 17.    Amendment. This Agreement may be amended or modified only
by a written instrument signed by the Executive and by a duly authorized representative of the Company. 

18.    Effect on Other Plans and Agreements. An election by the Executive to resign for Good Reason under the
provisions of this Agreement shall not be deemed a voluntary termination of employment by the Executive for the purpose of interpreting the provisions of any of the Company’s benefit plans, programs or policies. Nothing in this Agreement shall
be construed to limit the rights of the Executive under the Company’s benefit plans, programs or policies except as otherwise may be provided in Section 8 hereof, and except that the Executive shall have no rights to any severance benefits
under any Company severance pay plan, offer letter or otherwise. In the event that the Executive is party to an agreement with the Company providing for payments or benefits under such agreement and this Agreement, the terms of this Agreement shall
govern and the Executive may receive payment under this Agreement only and not both. Further, Section 5 and Section 6 of this Agreement are mutually exclusive and in no event shall the Executive be entitled to payments or benefits pursuant
to Section 5 and Section 6 of this Agreement. 
 19.    Governing Law. This is a Massachusetts contract
and shall be construed under and be governed in all respects by the laws of the Commonwealth of Massachusetts, without giving effect to the conflict of laws principles of such Commonwealth. With respect to any disputes concerning federal law, such
disputes shall be determined in accordance with the law as it would be interpreted and applied by the United States Court of Appeals for the First Circuit. 

20.    Assignment. Neither the Executive nor the Company may make any assignment of this Agreement or any interest
in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement (including the Restrictive Covenants Agreement) without the
Executive’s consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets;
provided further that if the purchaser in any transaction involving the transfer of all or substantially all of the Company’s assets assumes this Agreement and the Executive accepts a position with the purchaser that is equivalent or better to
his position immediately preceding such transaction, then the Executive shall not be entitled to any Severance Amount pursuant to Section 5 or any Change in Control Payment pursuant to Section 6. This Agreement shall inure to the benefit
of and be binding upon the Executive and the Company, and each of the Executive’s and the Company’s respective successors, executors, administrators, heirs and permitted assigns. 

21.    Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed
and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document. 

22.    Gender Neutral. Wherever used herein, a pronoun in the masculine gender shall be considered as including the
feminine gender unless the context clearly indicates otherwise. 
 [Signature Page Follows] 

  
 14 

 IN WITNESS WHEREOF, the parties have executed this Agreement effective on the Effective
Date. 
  

			
	MAGENTA THERAPEUTICS, INC.
		
	By:	 	 /s/ Kristen Stants

		 	Kristen Stants
	Its:	 	Chief People Officer

  

	
	EXECUTIVE
	
	 /s/ Jason Gardner

	Jason Gardner, D.Phil.

  
 15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}]]